# FDA staff flags data concerns about Capricor's therapy; shares plunge

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-27 18:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Executive Summary
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.

## Intelligence Brief
FDA documents have raised concerns regarding the data for Capricor's therapy, deramiocel, leading to a sharp decline in CAPR stock. BioSpace reports that the FDA disputes the company's assertions of success in Phase 3 trials for the Duchenne muscular dystrophy (DMD) treatment.


Coverage from Yahoo Finance highlights a divide among analysts regarding the probability of the therapy's approval. Simultaneously, legal firms including Kehoe Law Firm, P.C. and Holzer & Holzer, LLC have announced investigations into Capricor Therapeutics following the news.


Attention now turns to August 2026, the timeframe identified by RTTNews for the FDA's decision on biotech stocks including this therapy.

## Verified Facts & Key Claims
### What specific therapy is causing the controversy?
The therapy is deramiocel, a cell therapy intended for DMD.

### How has the market responded to the FDA documents?
According to Yahoo Finance, CAPR stock is on track for its worst day ever.

### When is the FDA's decision expected?
Coverage indicates a decision is expected in August 2026.

## Key People, Organizations & Locations
FDA, Capricor, CAPR Investor Alert Kehoe Law Firm P.C Investigates Capricor T, CAPR Stock On Track For Worst Day Ever, Analysts Divided On, Approval Probability After FDA Documents Paint, Biotech Stocks Facing FDA Decision In August, CAPR INVESTOR ALERT Investigation of Capricor Therapeutics Inc Announced

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| The National Law Review | CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T | 2026-07-27 15:32 | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxOQ3VpZ19FOWxLYzBaOVZJOU9nQ2l6bDJ0RHVOQVdicW1RaDEtUllvVER3MzRSWmowalVoUE1vbGVSSWNnei1FZVloQm1iWnNTbGdxd1dBQTd5Slk0Uk1STU4zVVA4ZnpQZ3BuOEFRVldCUnRQelZjWUxxblhtNlkwdndLcmdyYVZ4bUJFblV2MU5Sblo2VW9xSlZ2N3VqLWwwTDcyUHVKVFBvd0FFaUNxRkJR?oc=5) |
| Yahoo Finance | CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ | 2026-07-27 15:32 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxNV25pYXNyX3ZHVl9yVUZ1VFZDUjBoZEU1TEhuSG93OFlObm14UDBpSm50Zm9xbWhTWkF5S3kzN0huNEtYMTB3XzBfQ1JmRmpMakdxTjlMQVJOdTAtdE1vazRBTlpkMkpNVFJ4Z2dwZnFyU1JCdmRpSkNxSnFGNDdUNGhpRjhyQjJLZHpxQ3JZYTc?oc=5) |
| RTTNews | Biotech Stocks Facing FDA Decision In August 2026 | 2026-07-27 15:32 | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxPejEzNGE0WjVMU3dnaHVvQndkck5IaF9rTDNCWklWTTI5ZFNhR1VsWTE0dTFVaGxQemtaMEx3WmVyTFpYZnpVUW5yZThoZ2RUZE1oaXFsV3JFRFVtR3JEaFhvRzlETGppOFRuRHJsSnJ0ZG14WFRfalM2WkQxWXViZ1hjNUVWNmRlUmZVMlpUNA?oc=5) |
| GlobeNewswire | CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC | 2026-07-27 15:32 | [Source Link](https://news.google.com/rss/articles/CBMi-AFBVV95cUxOZVR4bHdmZE5BR2J5V0UzMHVmd0RpeVpFVzBJeE5KRXlxWUFyZWZhcE5wN2NtM05qc09LcW1PY2dNY3h4QjY3czlQRHVFSVlmR0ZLUUp1YzNna2JlN3hxN1dET1dIRFlCdzJCNEk5X2hjWTYybUFkWnRqVW10cngyOTZJamxCclFVcDE4aEV6MWNGSzRvcFdpRXJDc2x5YnRIWVRnY1RIWkdTbTFTbS1tbmtPVk5adjE1NXJ3M2dnam5hZW9EZFgyY096OUFtTEVaa2lya1Q1bkttdVZYM0ZwVVJ1ZHZXYmdDdkJwQUIyZ2lEcjJ4NVAySA?oc=5) |
| BioSpace | FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy | 2026-07-27 15:32 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxNRkUzS1hSNTg1RC12NGxidVczTzVSVXo5ZjZ2RDVVTGtac2Fnb2R2UmRIX01ia0JRY3NwUW5keDZsSkJuZWdkQjlQbnlpMlNVbldIaWllTk5ibFlTUFpnLWFXTGM2UXRZaC1fWm13b2dOaHJ6SU5oUnhZN214MmxDMEY3UnRYMGVyVzlQdGlsajhVanE4VExPLVBrTzhmTFlRZkIwNWlHRlk2RVkwVGk3Yw?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-27/fda-staff-flags-data-concerns-about-capricor-s-therapy-shares-plunge*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*